In an exclusive interview with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London on March 19, Roberto Formisano, Senior Process Transfer Manager at AGC Biologics, discussed the challenges associated with technology transfer.

Roberto highlighted the complexities involved in transferring technology from development to GMP manufacturing and from customer to contract development and manufacturing organization (CDMO). He explained how critical time frames pose the biggest challenge in this field, and that balancing the number of batches to be produced is essential to ensure sufficient and scientifically quality data within these deadlines.

Roberto also shared his insights into the technology and product trends and priorities he foresees for the cell and gene therapy industry in 2024. He emphasized the importance of staying up-to-date with advancements in this rapidly evolving field to remain competitive.

Overall, Roberto’s interview provided valuable insights into the nuances of technology transfer and its implications for industry. His expertise in this area makes him a valuable resource for companies looking to navigate these challenges effectively.

By Samantha Johnson

As a dedicated content writer at, I immerse myself in the art of storytelling through words. With a keen eye for detail and a passion for crafting engaging narratives, I strive to captivate our audience with each piece I create. Whether I'm covering breaking news, delving into feature articles, or exploring thought-provoking editorials, my goal remains constant: to inform, entertain, and inspire through the power of writing. Join me on this journalistic journey as we navigate through the ever-evolving media landscape together.

Leave a Reply